LSTA צמיחת רווח למניה בשנה הנוכחית Lisata

Lisata Therapeutics (LSTA) is implementing AI analysis and automated testbeds to accelerate research, as illustrated by the annual net income per share trend, where the current value is 0.00. The company is developing treatments for solid tumors in the US by improving drug delivery. The development of pancreatic cancer therapy relies on clinical trials and strategic alliances with global pharma behemoths.
פילוחים אנליטיים ודוחות נתונים של חברת lisata.com (LSTA)

Lisata Therapeutics (LSTA) operates within a stringent FDA regulatory environment, leveraging its protected iCend platform. The EPS YoY trend measures the annual change in net income per share, reflecting the actual efficiency of intellectual property capitalization. Analyzing the relative EPS YoY trend allows for an assessment of the business's ability to generate income despite trial costs. Growth in this metric confirms the monetization of patents, while an upward trajectory indicates the company's fundamental stability.